Cantitate/Preț
Produs

Statistical Methods for Immunogenicity Assessment: Chapman & Hall/CRC Biostatistics Series

Autor Harry Yang, Jianchun Zhang, Binbing Yu, Wei Zhao
en Limba Engleză Hardback – 3 sep 2015
Develop Effective Immunogenicity Risk Mitigation Strategies
Immunogenicity assessment is a prerequisite for the successful development of biopharmaceuticals, including safety and efficacy evaluation. Using advanced statistical methods in the study design and analysis stages is therefore essential to immunogenicity risk assessment and mitigation strategies. Statistical Methods for Immunogenicity Assessment provides a single source of information on statistical concepts, principles, methods, and strategies for detection, quantification, assessment, and control of immunogenicity.
The book first gives an overview of the impact of immunogenicity on biopharmaceutical development, regulatory requirements, and statistical methods and strategies used for immunogenicity detection, quantification, and risk assessment and mitigation. It then covers anti-drug antibody (ADA) assay development, optimization, validation, and transfer as well as the analysis of cut point, a key assay performance parameter in ADA assay development and validation. The authors illustrate how to apply statistical modeling approaches to establish associations between ADA and clinical outcomes, predict immunogenicity risk, and develop risk mitigation strategies. They also present various strategies for immunogenicity risk control. The book concludes with an explanation of the computer codes and algorithms of the statistical methods.
A critical issue in the development of biologics, immunogenicity can cause early termination or limited use of the products if not managed well. This book shows how to use robust statistical methods for detecting, quantifying, assessing, and mitigating immunogenicity risk. It is an invaluable resource for anyone involved in immunogenicity risk assessment and control in both non-clinical and clinical biopharmaceutical development.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 33209 lei  3-5 săpt.
  CRC Press – 18 dec 2020 33209 lei  3-5 săpt.
Hardback (1) 52790 lei  3-5 săpt.
  CRC Press – 3 sep 2015 52790 lei  3-5 săpt.

Din seria Chapman & Hall/CRC Biostatistics Series

Preț: 52790 lei

Preț vechi: 74480 lei
-29%

Puncte Express: 792

Preț estimativ în valută:
9343 10919$ 8111£

Carte disponibilă

Livrare economică 30 ianuarie-13 februarie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781498700344
ISBN-10: 1498700349
Pagini: 259
Ilustrații: 52 black & white illustrations, 39 black & white tables
Dimensiuni: 156 x 234 x 20 mm
Greutate: 0.5 kg
Ediția:1
Editura: CRC Press
Colecția Chapman and Hall/CRC
Seria Chapman & Hall/CRC Biostatistics Series


Cuprins

Introduction. ADA Assay Development and Validation. Determination of ADA Assay Cut Point. Clinical Immunogenicity Assessment. Immunogenicity Risk Control. Computational Tools for Immunogenicity Analysis. Bibliography. Index.

Notă biografică

Harry Yang is a senior director, Jianchun Zhang is a principal statistician, Binbing Yu is an associate director, and Wei Zhao is a senior principal statistician at MedImmune, LLC in Gaithersburg, Maryland, USA.

Recenzii

"In summary, this book is a good resource to the professionals and practitioners developing the biological therapies, including statisticians, clinicians, pharmacokineticists, regulatory reviewers, toxicologists, clinical assay developers, and biopharmaceutical engineers."
~Journal of Biopharmaceutical Statistics
"The authors' work brings light into some of the issues surrounding immunogenicity of drugs. It is of great help to both clinical and nonclinical professionals, while some of the concepts can also be applied to situations when an immune response towards a drug (a vaccine) is desirable."
~Paul Tudor Tamas

Descriere

A critical issue in the development of biologics, immunogenicity can cause early termination or limited use of the products if not managed well. This book shows how to use robust statistical methods for detecting, quantifying, assessing, and mitigating immunogenicity risk. Along with covering regulatory requirements, the authors discuss statistical considerations in assay development. They also address the challenges of the cut point performance parameter in practical clinical sample testing. The included computer codes and algorithms facilitate application of the statistical methods.